iBioIBIO
Market Cap: $16.4M
About: iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.
Employees: 23
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 28 [Q1] → 28 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
50% less capital invested
Capital invested by funds: $11.4M [Q1] → $5.68M (-$5.76M) [Q2]
51.69% less ownership
Funds ownership: 82.92% [Q1] → 31.23% (-51.69%) [Q2]
73% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 11
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Brookline Capital Kemp Dolliver 29% 1-year accuracy 2 / 7 met price target | 89%upside $3.60 | Buy Initiated | 22 Jul 2024 |